retatrutide news today recency 3 Retatrutide, an experimental weight-loss drug, has not been approved by Phase III retatrutide study demonstrates

T0 and T1 included only one blood tube for THC and hormones, respectively

A concerning side effect and its impact, especially for those over 50 The well-known side effects include nausea and gastrointestinal issues

Importantly, most GLP-1 receptor agonists carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

If ultrasound is available and no gastric contents are appreciated, it is recommended to proceed with the procedure

Retatrutide further reduced plasma alanine aminotransferase and liver triglycerides, suggesting improvements in liver health [42]

This study proposes that this phenomenon may arise from peripheral and central GLP-1 receptor hyperstimulation, leading to downregulation of chemosensory pathways (165)